All In Biotech

Drug Trial Radar · NCT04614740

The Phase I/Phase II Clinical Study of VC004 in Patients With Localized Advanced/Metastatic Solid Tumors

Single-arm, Open, Multi-center Phase I/Phase II Clinical Study to Assess the Safety, Tolerability, Pharmacokinetic and Effectiveness of VC004

Last checked: Nov 19, 2026Latest source record: Dec 13, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

115

Planned (sponsor's estimate)

Start

Nov 20, 2020

Primary completion

Jan 31, 2024

Study completion Jun 30, 2024

Sponsor

Sponsor type
Industry
First posted
Nov 4, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Dose-escalation study will be conducted in patients with locally advanced/metastatic solid tumors who have failed standard treatment, or cannot tolerate standard treatment, or have no recommended standard treatment, or do not apply standard treatment, to evaluate the safety, PK, tolerability and effectiveness of VC004. According to the efficacy, safety and PK of dose-escalation study , the investigator and the sponsor jointly determine the dose for dose extension, and evaluate the anti-tumor effect of VC004 on NTRK fusion-positive subjects, and provide more information for RP2D. According to the tolerability and pharmacokinetic results of dose-escalation study , an appropriate dose or MTD will be selected, namely RP2D, to further assess anti-tumor efficacy and safety in patients with NTRK fusion-positive locally advanced/metastatic solid tumors . ORR will be chosen as the main efficacy indicator to evaluate the anti-tumor efficacy and safety of VC004 .

Conditions

  • Locally Advanced Solid Tumor
  • Metastatic Solid Tumor

Interventions

  • VC004Drug

    25 mg capsules,50 mg capsules,100 mg capsules.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety&TolerabilityTime frame: 4 years
  2. Phase II recommended dose(RP2D)Time frame: 1.5 years
  3. Maximum tolerated dose(MTD)(If any)Time frame: 1.5 years
  4. Objective response rate(ORR)Time frame: 4 years

Locations

21 sites in 1 country. Site status is shown where the registry gives one.

  • Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College

    Beijing, China · Recruiting

  • Zhujiang Hospital of Southern Medical University

    Guangzhou, China · Recruiting

  • Liaoning Cancer Hospital & Institute

    Shenyang, China · Recruiting

  • Tianjin Cancer Hospital

    Tianjin, China · Recruiting

  • The First Affiliated Hospital of Xinjiang Medical University

    Ürümqi, China · Recruiting

  • Hubei Cancer Hospital

    Wuhan, China · Recruiting

  • Anhui Provincial Cancer Hospital

    Hefei, Anhui, China · Not yet recruiting

  • Chongqing University Cancer Hospital

    Chongqing, Chongqing Municipality, China · Not yet recruiting

  • Fujian Cancer Hospital

    Fuzhou, Fujian, China · Not yet recruiting

  • Guangxi Medical University Affiliated Tumor Hospital

    Nanning, Guangxi, China · Not yet recruiting

  • Hainan Cancer Hospital

    Haikou, Hainan, China · Not yet recruiting

  • The Fourth Hospital of Hebei Medical University

    Shijiazhuang, Hebei, China · Not yet recruiting

  • Harbin Medical Univercity Cancer Hospital

    Harbin, Heilongjiang, China · Not yet recruiting

  • Henan Cancer Hospital

    Zhengzhou, Henan, China · Recruiting

  • Hunan Cancer Hospital

    Changsha, Hunan, China · Recruiting

  • Jiangsu Province Hospital of Chinese Medicine

    Nanjing, Jiangsu, China · Recruiting

  • Shandong Cancer Hospital

    Jinan, Shandong, China · Not yet recruiting

  • Shanghai Tenth People's Hospital

    Shanghai, Shanghai Municipality, China · Not yet recruiting

  • Shanxi Provincial Cancer Hospital

    Taiyuan, Shanxi, China · Not yet recruiting

  • Yunnan Cancer Hospital

    Kunming, Yunnan, China · Not yet recruiting

  • Zhejiang Cancer Hospital

    Hangzhou, Zhejiang, China · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.